Enzalutamide 40 MG Oral Capsule [Xtandi] — RxCUI 1307309
RxNorm drug concept · Semantic branded drug
RxCUI 1307309
Semantic branded drug · SBD
● Current RxNorm concept 5 FDA products
5 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1307309
Official nameEnzalutamide 40 MG Oral Capsule [Xtandi]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asXtandi 40 MG Oral Capsule
FDA products mapped5
Package NDCs mapped5
Reported Medicaid activity (SDUD)9,669 prescriptions · 36 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Enzalutamide: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Enzalutamide — sold as Xtandi — is approved for treating prostate cancer at different stages. It's used when the cancer is still sensitive to hormone therapy (castration-sensitive)...
- What exactly is enzalutamide being used to treat in my case?
- You can take Xtandi with or without food — it doesn't make a meaningful difference in how well the drug is absorbed. What matters most is that you take it at roughly the same time...
- Does it matter when I take it or whether I take it with food?
🕸️ Concept Web — How Enzalutamide 40 MG Oral Capsule [Xtandi] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Enzalutamide 40 MG Oral Capsule [Xtandi]
RxCUI 1307309 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Enzalutamide
1307298IN
-
Enzalutamide
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Xtandi
1307304BN
-
Xtandi
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Enzalutamide Oral Capsule
1307302SCDF -
Enzalutamide Oral Product
1307300SCDG -
Enzalutamide Pill
1307301SCDG -
Enzalutamide Oral Capsule [Xtandi]
1307306SBDF -
Xtandi Oral Product
1307307SBDG -
Xtandi Pill
1307308SBDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG - +1 more in this family
-
Enzalutamide Oral Capsule
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Enzalutamide 40 MG Oral Capsule
1307303SCD -
Enzalutamide 40 MG
1307299SCDC -
Enzalutamide 40 MG [Xtandi]
1307305SBDC
-
Enzalutamide 40 MG Oral Capsule
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Enzalutamide 40 MG Oral Capsule
SCD · 1307303 -
Enzalutamide 40 MG
SCDC · 1307299 -
Enzalutamide Oral Capsule
SCDF · 1307302 -
Enzalutamide Oral Product
SCDG · 1307300 -
Enzalutamide Pill
SCDG · 1307301
Brand-Name Concepts
-
Enzalutamide 40 MG [Xtandi]
SBDC · 1307305 -
Enzalutamide Oral Capsule [Xtandi]
SBDF · 1307306 -
Xtandi Oral Product
SBDG · 1307307 -
Xtandi Pill
SBDG · 1307308 -
Xtandi
BN · 1307304
📦 FDA Products & Package NDCs
5 products · 5 package NDCs
5 package NDCs map to RxCUI 1307309 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00469-0125-99 | 1 BOTTLE in 1 CARTON (0469-0125-99) / 120 CAPSULE in 1 BOTT... | Xtandi | Astellas Pharma US, Inc. | 2012-08-31 |
| 00469-0625-99 | 1 BOTTLE in 1 CARTON (0469-0625-99) / 120 TABLET in 1 BOTTL... | Xtandi | Astellas Pharma US, Inc. | 2020-08-04 |
| 00469-0725-60 | 1 BOTTLE in 1 CARTON (0469-0725-60) / 60 TABLET in 1 BOTTLE | Xtandi | Astellas Pharma US, Inc. | 2020-08-04 |
| 00469-1125-56 | 56 CAPSULE in 1 BLISTER PACK (0469-1125-56) | Xtandi | Astellas Pharma US, Inc. | 2012-08-31 |
| 00469-1725-56 | 1 BOTTLE in 1 CARTON (0469-1725-56) / 56 TABLET in 1 BOTTLE | Xtandi | Astellas Pharma US, Inc. | 2020-08-04 |
Observed labelers:
Astellas Pharma US, Inc. (5)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.